STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca’s hypertension drug, and more biotech news from The Readout AP/Business Wire Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we regale you with mid-August delights from the EMA, ICER, and a federal appeals court. Hope you had a lovely weekend. My kids went to Disneyland, an aquarium, and the beach — but now seem thrilled most of all by the television. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.